Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a randomized, double-blind, controlled trial
- PMID: 6143340
- DOI: 10.1017/s0033291700003068
Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a randomized, double-blind, controlled trial
Abstract
A detailed analysis of the results of a multi-centre clinical trial shows that, while the relapse rate following recovery from an operationally defined depressive illness was smaller among patients subsequently treated with either amitryptiline or lithium than with a placebo, there was no clinically significant difference between the prophylactic efficacy of the 2 antidepressants. An account is given of the relative adverse effects of the treatments, and the implications of the findings are discussed.